Tremelimumab is another CTLA4 mAb recently approved by the FDA in combination with durvalumab and platinum-based chemotherapy in metastatic NSCLC without EGRF and ALK gene mutations. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.